NASDAQ$SCPH
scPharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
scPharmaceuticals' Q2 2024 financial results were announced, featuring FUROSCIX revenue growth and progress in life cycle management.
scPharmaceuticals reported Q2 2024 net FUROSCIX revenue of $8.1 million, a 33% increase sequentially, with approximately 9,300 FUROSCIX doses filled. The company completed financing to extend cash runway through expected profitability and advanced FUROSCIX growth initiatives, including label expansion and sNDA submissions.
- Net FUROSCIX revenue reached $8.1 million, up 33% sequentially from Q1 2024.
- Approximately 9,300 FUROSCIX doses were filled, a 15% sequential increase from Q1 2024.
- FDA approval was received to expand the FUROSCIX indication to include patients with NYHA Class IV chronic heart failure.
- Positive topline PK/PD data was announced for the FUROSCIX autoinjector, with an sNDA submission targeted by the end of the year.
Headline financials
Revenue & EPS history
scPharmaceuticals · Revenue · Quarterly
$8.05M
Revenue by segment
scPharmaceuticals · $3.8M total across 1 segment · Q3 2023
- FUROSCIX$3.8M—100.0%
Forward guidance
scPharmaceuticals anticipates continued growth and progress with FUROSCIX, supported by recent FDA approvals, positive clinical data, and transformational financing, extending the cash runway through profitability.
Tailwinds
- FDA approval to expand FUROSCIX indication to include NYHA Class IV heart failure patients.
- Positive PK/PD data from a study of the low volume autoinjector, with sNDA submission targeted by the end of the year.
- FDA acceptance of sNDA seeking to expand FUROSCIX label into chronic kidney disease.
- Completed transformational financing with healthcare-focused institutional investors.
- Financing extends cash runway through profitability.
Headwinds
- Dependence on the commercial success of FUROSCIX and other product candidates.
- Risks related to receipt of regulatory approval for product candidates.
- Risks related to the ability to manufacture sufficient product for commercialization.
- History of operating losses and expectation to incur significant and increasing losses.
- The terms of our credit facility place restrictions on our operating and financial flexibility
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q2 2024
+3.8%
Avg return
Earnings day
+5.8%
Avg return
5 days after
+7.1%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+52.7%
Q4 2019
Best reaction
-14.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | -7.4% | -4.6% | +11.6% | |
| Q1 2025 | +27.4% | +45.1% | +74.8% | |
| Q4 2024 | -1.0% | -1.3% | -15.5% | |
| Q3 2024 | -14.5% | -14.8% | -18.6% | |
| Q2 2024 | +2.6% | +3.7% | +11.8% | |
| Q1 2024 | +5.1% | +10.6% | -6.9% | |
| Q4 2023 | -1.1% | +2.2% | -7.8% | |
| Q3 2023 | -8.4% | — | — | |
| Q2 2023 | +0.0% | — | — | |
| Q1 2023 | -0.6% | — | — | |
| Q4 2022 | +25.0% | — | — | |
| Q3 2022 | +7.3% | — | — | |
| Q2 2022 | +8.6% | — | — | |
| Q1 2022 | +7.7% | — | — | |
| Q4 2021 | +7.0% | — | — | |
| Q3 2021 | -10.1% | — | — | |
| Q2 2021 | +4.9% | — | — | |
| Q1 2021 | -5.3% | — | — | |
| Q4 2020 | -6.6% | — | — | |
| Q3 2020 | +2.0% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | -4.0% | — | — | |
| Q4 2019 | +52.7% | — | — | |
| Q3 2019 | -5.4% | — | — | |
| Q2 2019 | +10.1% | — | — | |
| Q1 2019 | +0.6% | — | — | |
| Q4 2018 | -4.8% | — | — | |
| Q3 2018 | +1.2% | — | — | |
| Q2 2018 | +2.9% | — | — | |
| Q1 2018 | +29.2% | — | — | |
| Q4 2017 | -6.7% | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro